Program Director/Principal Investigator (Last, First, Middle): Overton, Edgar Turner Abstract: The Alabama CRS is intimately involved in the response to the Alabama COVID-19 epidemic. Our research team is currently involved in multiple components of the local response, including COVID-19 testing for diagnosis, antibody testing for epidemiology and for the development of therapeutic and preventive therapies, contact tracing of COVID-19 patients, outpatient and inpatient management of COVID-19 patients, employee health initiatives to prevent COVID-19 among our healthcare workers, expanded testing in the community (particularly to marginalized populations), providing education both within our institution and to the outside community, as well as leading research initiatives in the state of Alabama. In our efforts to flatten the curve and mitigate COVID-19 disease in our state, we desperately need additional resources, including additional staffing, additional testing capacity for both PCR and antibody testing, and reagents to complete that work. This supplement provides our team the very resources needed to achieve these aims. For this proposal, we will augment our ongoing efforts with the following projects. We are adding two nurse practitioners to our team. With their level of experience, they will assist with several aspects of the proposal, including expanded testing in community and for research studies, identifying acute and convalescent patients to perform both PCR testing and blood draws to facilitate an understanding of viral kinetics, as well as the evolution of host responses in COVID-19 patients. The data and virologic and serologic samples will provide key insight in to the distribution and natural history of COVID-19 among both rural and urban settings in Alabama. Additionally, these data will inform a greater understanding of the host-viral interaction and host factors that contribute to severity of disease. Currently, we have very little testing being performed outside of the urban centers and have very little understanding of our rural areas. Dr. Heath has partnered with Dr. Barbara Van Der Pol and her molecular diagnostics lab to increase testing capacity for our institution and Alabama, at large. Their laboratory team have the capacity to perform an additional 200 PCR tests per day. We will leverage this laboratory infrastructure to enhance testing for populations that are unable to come to testing sites in our urban centers. In addition, Dr. Heath?s lab has expanded capacity to develop sensitive, specific antibody testing approaches to characterize the natural history of disease, and more importantly to identify donors for life-saving plasma donation. These initiatives will also inform the search for surrogates of protection among convalescent COVID-19 patients and the search for vaccine-elicited immunity, as well as monoclonal antibodies. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page Continuation Format Page

Public Health Relevance

Overton, Edgar Turner Narrative: Additional resources are needed to flatten the curve and mitigate COVID-19 disease in our state as we currently have very little testing performed outside of the urban centers and little understanding of the impact to our rural areas. Resources such as additional staffing, testing capacity, and reagents will be provided through this proposal to achieve these aims. OMB No. 0925-0001/0002 (Rev. 03/2020 Approved Through 02/28/2023) Page Continuation Format Page

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Program Officer
Pouliot, Eileen M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Salantes, D Brenda; Zheng, Yu; Mampe, Felicity et al. (2018) HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J Clin Invest 128:3102-3115
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Tassiopoulos, Katherine; Abdo, Mona; Wu, Kunling et al. (2017) Frailty is strongly associated with increased risk of recurrent falls among older HIV-infected adults. AIDS 31:2287-2294
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60
Robbins, Gregory K; Cohn, Susan E; Harrison, Linda J et al. (2016) Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251. HIV Clin Trials 17:165-72
Chan, Ellen S; Landay, Alan L; Brown, Todd T et al. (2016) Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS 30:2091-7

Showing the most recent 10 out of 72 publications